X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (26) 26
index medicus (26) 26
female (21) 21
oncology (21) 21
aged (19) 19
male (19) 19
adult (18) 18
middle aged (18) 18
article (14) 14
cancer (14) 14
lymphomas (14) 14
care and treatment (12) 12
aged, 80 and over (11) 11
dose-response relationship, drug (9) 9
chemotherapy (8) 8
hematology (8) 8
patients (8) 8
treatment outcome (8) 8
abridged index medicus (7) 7
maximum tolerated dose (7) 7
neoplasms - drug therapy (7) 7
rituximab (7) 7
tumors (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
drug administration schedule (6) 6
young adult (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
lymphoma (5) 5
lymphoma, large b-cell, diffuse - drug therapy (5) 5
proteins (5) 5
recurrence (5) 5
animals (4) 4
antineoplastic agents - pharmacokinetics (4) 4
antineoplastic agents - pharmacology (4) 4
antineoplastic agents - therapeutic use (4) 4
b-cell lymphoma (4) 4
clinical trials (4) 4
disease-free survival (4) 4
dose-escalation (4) 4
drug therapy (4) 4
expression (4) 4
inhibitor (4) 4
inhibitors (4) 4
lymphoma - drug therapy (4) 4
neoplasms - metabolism (4) 4
neoplasms - pathology (4) 4
neutropenia (4) 4
pharmacokinetics (4) 4
pharmacology & pharmacy (4) 4
research (4) 4
studies (4) 4
sulfonamides - adverse effects (4) 4
adolescent (3) 3
advance care planning (3) 3
advanced cancer (3) 3
aminopyridines - therapeutic use (3) 3
analysis (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
apoptosis (3) 3
art (3) 3
breast-cancer (3) 3
bridged bicyclo compounds, heterocyclic - administration & dosage (3) 3
bridged bicyclo compounds, heterocyclic - adverse effects (3) 3
calendars (3) 3
cancer therapies (3) 3
cell line, tumor (3) 3
cell survival (3) 3
chronic lymphocytic-leukemia (3) 3
clonal deletion (3) 3
code status (3) 3
crm1 (3) 3
decision-making (3) 3
disease (3) 3
diseases (3) 3
dosage and administration (3) 3
drug dosages (3) 3
end-of-life decision-making (3) 3
exhibitions (3) 3
festivals (3) 3
hematology, oncology and palliative medicine (3) 3
hemic and lymphatic diseases (3) 3
hsp90 heat-shock proteins - metabolism (3) 3
lymphoma, non-hodgkin - drug therapy (3) 3
morpholines - adverse effects (3) 3
museums (3) 3
non-hodgkins-lymphoma (3) 3
package tours (3) 3
patient outcomes (3) 3
pharmacology (3) 3
phase-i (3) 3
planning (3) 3
preferences (3) 3
prognosis (3) 3
relapse (3) 3
resuscitation (3) 3
services (3) 3
special events (3) 3
sulfonamides - administration & dosage (3) 3
sulfonamides - pharmacokinetics (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 311 - 322
An oral inhibitor of BCL2 produces substantial responses in the majority of patients with refractory chronic lymphocytic leukemia. The agent is so effective... 
DOSE-ESCALATION | APOPTOSIS | MEDICINE, GENERAL & INTERNAL | CLL | INTERNATIONAL WORKSHOP | CYCLOPHOSPHAMIDE | RITUXIMAB | IBRUTINIB | INHIBITOR | PHASE-I | FLUDARABINE | Recurrence | Humans | Middle Aged | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antineoplastic Agents - administration & dosage | Remission Induction | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Disease-Free Survival | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Sulfonamides - adverse effects | Adult | Female | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Antineoplastic Agents - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Antimitotic agents | Treatment outcome | Care and treatment | Usage | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Dosage and administration | Antineoplastic agents | Pharmacokinetics | Risk factors | Flow cytometry | Chronic lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Diarrhea | Chromosome deletion | Nausea | Lymphatic leukemia | Lymphoma | Patients | Proteins | Chemotherapy | Fludarabine | Clonal deletion | Lysis | Respiratory tract diseases | Lymphomas | Chromosome 17 | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2017, Volume 35, Issue 8, pp. 826 - 833
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 12, pp. 1149 - 1159
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 12, pp. 1107 - 1120
In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | INDEPENDENT PREDICTOR | 17P DELETION | TARGETING BCL2 | PLUS RITUXIMAB | TP53 MUTATION | PROGRESSION-FREE | OPEN-LABEL | MINIMAL RESIDUAL DISEASE | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Neoplasm, Residual | Young Adult | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Kaplan-Meier Estimate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Treatment outcome | Chronic lymphocytic leukemia | Diagnosis | Analysis | Chronic lymphatic leukemia | Cell survival | Hematology | Leukemia | Rituximab | Clinical trials | Oncology | Chromosome deletion | Lymphatic leukemia | Patients | Cancer therapies | Chemotherapy | Clonal deletion | Lysis | Response rates | Bone marrow | Chromosomes | Drug dosages | Chromosome 17 | Neutropenia | Life Sciences | Cancer
Journal Article
Nature, ISSN 0028-0836, 2016, Volume 538, Issue 7625, pp. 397 - 401
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 622 - 631
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2018, Volume 24, Issue 18, pp. 4371 - 4379
Purpose: The oral BCL-2 inhibitor venetoclax is an effective therapy for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including... 
BCL2 | LYMPHOMA | ONCOLOGY | INHIBITOR | PHASE-I | TUMOR LYSIS SYNDROME
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2017, Volume 23, Issue 6, pp. 1552 - 1563
Journal Article